Telehealth provides more flexibility for patients with gastrointestinal issues to better fit their care into their lives and around symptoms they may be experiencing, said Sam Holliday, co-founder and CEO of Oshi Health.
A study published this month in Journal of the National Comprehensive Cancer Network shows telehealth visits consistently outperformed in-person visits in cancer care when both were available. Here, Sam Holliday, co-founder and CEO of Oshi Health, explains the most important takeaways from this study and how these findings translate to gastroenterology care.
Transcript
What are the most important takeaways from the NCCN study that found telehealth outperformed in-person visits in cancer care?
We get feedback all the time, that's very similar, that not everyone wants to use virtual all the time. But for many of these things where you need more frequent visits, to fit those into people's daily lives is easier sometimes through telehealth. I think that was referenced in the study.
Beyond that, when you're experiencing symptoms like chronic diarrhea, many people that we treat are afraid to leave their home, so asking them to come for in-person visits is very challenging. They're worried about the drive to the office, especially if they're in a rural area and that's a longer drive; that's going to create anxiety [and] anxiety can trigger the symptoms. So if you think about it from that perspective, then how long am I going to be waiting in the waiting room to see somebody?
Virtual is really great, because you remove all those steps. Someone can do it from the convenience of home without worry about access to a bathroom. If they need to pause the visit in the middle because they have to go to the bathroom, you could do things like that. It just provides a lot more flexibility for people to fit it into their lives and around symptoms they might be experiencing.
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More